Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Fate Therapeutics, Inc.
Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital
May 30th, 2009
Fate Therapeutics, Inc. announced that it has acquired exclusive intellectual property rights jointly owned by Children's Hospital Boston and Massachusetts General Hospital. This intellectual property covers compositions and methods for supporting hematopoietic stem cells. These proprietary technologies developed by Leonard Zon, M.D., director of the Stem Cell Program at Children's Hospital Boston and a scientific founder of Fate Therapeutics, expand the Company's broad intellectual property portfolio for modulating the activity and state of stem cells. Fate Therapeutics is utilizing its adult stem cell biology engine and induced pluripotent stem (iPS) cell technology platform to develop...
Source: Law & Health Weekly (2009-05-30)
|
|
Advertisement |
|
|
|
